The global endoscopic retrograde cholangiopancreatography market size was valued at $1,212.94 million in 2019, and is projected to reach $1,876.75 million by 2027, registering a CAGR of 5.6% from 2019 to 2027.
Endoscopy is a clinical process to observe body tissue or internal organs in detail or to conduct some minor surgery. Endoscopic retrograde cholangiopancreatography (ERCP) devices are medical equipment designed for pancreas to biliary system related disorders. These devices are gaining increased importance and adoption due to surge in prevalence of various bile ducts, and pancreatic and liver disorders such as Barrett's Disease., Biliary Disease, Colitis, Crohn's Disease, Gastroesophageal Reflux Disorder (GERD), liver Disease, Pancreatitis, Inflammatory Bowel Disease, Crohn’s Disease, Peptic Ulcer Disease.
The COVID-19 pandemic has had a major global impact on endoscopic services. Furthermore, the infection is transmitted through contact and droplets. Therefore, healthcare providers of endoscopy are facing tremendous risk during the pandemic as the spread is mainly through direct contact or aerosol droplets, and endoscopy procedures require a short physical distance between patients and personnel. A report from Hong Kong, based on experience with SARS, showed that the risk of infection is 5% for physicians, 4% for nurses, and 8% for healthcare assistants. It emphasized the importance of practicing strict isolation, infection control measures, and adherence to use of personal protective equipment (PPE). Hence, the endoscopic retrograde cholangiopancreatography market is negatively impacted by the COVID-19 pandemic.
The growth of the global endoscopic retrograde cholangiopancreatography (ERCP) market is majorly driven by rise in incidences of gastrointestinal and chronic biliary disorders such as Barrett's disease, biliary disease, colitis, Crohn's disease, gastroesophageal reflux disorder (GERD), liver Disease, pancreatitis, inflammatory bowel disease, and peptic ulcer disease. Further, rapid increasing frequencies of benign tumors of the liver and pancreas coupled with an increase in ageing population and surge in awareness related to devices used in ERCP for treatment of disorders. However, high costs associated with treatment from ERCP and side-effects of the procedure such as post-ERCP pancreatitis are expected to hamper the growth of the endoscopic retrograde cholangiopancreatography market. On the contrary, emerging countries possess high growth potential, owing to improvement of healthcare infrastructures in these countries.
By product type, the endoscopic retrograde cholangiopancreatography (ERCP) market segmented into endoscopes, endotherapy devices, imaging systems, energy devices, and others. Further, endotherapy devices is divided into sphincterotome, lithotripter, stents, cannulas, forceps, snares, catheters, guiding wires, balloons, baskets, and others. By application, it is divided into biliary sphincterotomy, biliary dilatation, biliary stenting, pancreatic sphincterotomy, pancreatic duct dilatation, and pancreatic duct stenting. By end user, it is segregated into hospitals & clinics, ambulatory surgery centers, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The North America endoscopic retrograde cholangiopancreatography market accounted for the largest share in 2019 followed by Europe; however, the Asia-Pacific region is anticipated to grow with the highest CAGR during the forecast period.
Product Type segment review
By product type, the endotherapy devices segment held the largest share in 2019 and is anticipated to maintain its dominance during the forecast period, owing to increase in demand for ERCP therapeutics procedures, and rise in prevalence of choledocholithiasis, gallbladder stones, pancreatitis, and other bile duct & pancreatic duct diseases. Further, by endotherapy devices, the stents and sphincterotome segments held the largest share in 2019 and is estimated to grow at a CAGR of 3.7% and 3.8% respectively during the forecast period.
By Product Type
Endotherapy Devices segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.
Application segment review
On the basis of application, the pancreatic sphincterotomy segment is expected to register highest CAGR during the forecast period, owing to increase in prevalence of population suffering from obstructing ductal calculi, ductal disruption & leak, sphincter stenosis, and dominant stricture of pancreas. Moreover, rise in demand for endoscopic technique which is used for various pancreas and pancreas-related diseases further fuels the growth of the endoscopic retrograde cholangiopancreatography market.
By Application
Surface Markers Separation Segment is projected as one of the most lucrative segment.
Region segment review
By region, North America accounted for the largest share in 2019, and is anticipated to maintain its dominance from 2019 to 2027, due to high expenditure on R&D, presence of major players & their product availability, and well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to register the highest CAGR during the forecast period, as Governments of Asian countries are investing in the development of healthcare infrastructure.
By Region
Asia Pacific region would exhibit the highest CAGR of 7.0% during 2019-2027.
Some of the key players operating in the global endoscopic retrograde cholangiopancreatography market include Olympus Corporation, Conmed Corporation, Hobbs Medical, Inc., TeleMed Systems, Inc., Boston Scientific Corporation, Cook Group Incorporation, Ambu, Inc., Becton, Dickinson and Company, Fujifilm Holding Corporation, and Medtronic Plc.
Key Benefits For Stakeholders
- This report entails a detailed quantitative analysis along with the current global endoscopic retrograde cholangiopancreatography market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
- The endoscopic retrograde cholangiopancreatography market forecast is studied from 2019 to 2027.
- The endoscopic retrograde cholangiopancreatography market size and estimations are based on a comprehensive analysis of key developments in the endoscopic retrograde cholangiopancreatography industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the endoscopic retrograde cholangiopancreatography market.
Key Market Segments
By Product Type
- Endoscopes
- Endotherapy Devices
- Sphincterotome
- Lithotripter
- Stents
- Cannulas
- Forceps
- Snares
- Catheters
- Guiding Wires
- Balloons
- Baskets
- Others
- Imaging Devices
- Energy Devices
- Others
By Application
- Biliary Sphincterotomy
- Biliary Dilatation
- Biliary Stenting
- Pancreatic Sphincterotomy
- Pancreatic Duct Dilatation
- Pancreatic Duct Stenting
By End User
- Hospitals & Clinics
- Ambulatory Surgery Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Endoscopic Retrograde Cholangiopancreatography Market Report Highlights
| Aspects | Details |
 By PRODUCT TYPE |
|
 By APPLICATION |
|
 By END USER |
|
 By Region |
|
 Key Market Players | AMBU INC., COOK GROUP INCORPORATION, HOBBS MEDICAL, INC., BOSTON SCIENTIFIC CORPORATION., FUJIFILM HOLDINGS CORPORATION., MEDTRONIC PLC., BECTON, DICKINSON AND COMPANY, CONMED CORPORATION., TELEMED SYSTEM, INC., OLYMPUS CORPORATION |
Analyst Review
In accordance to several interviews conducted, the endoscopic retrograde cholangiopancreatography market is expected to witness a steady growth in the future. The market has drawn the interest of the healthcare industry, owing to increase in prevalence of choledocholithiasis, gallbladder stones, pancreatitis, and other bile duct & pancreatic duct diseases globally. The endoscopic retrograde cholangiopancreatography market is dominated by well-established players; hence, the market is anticipated to witness intense competition. The adoption of these devices has increased considerably, owing to adoption of technological advanced medical devices in the ERCP procedures, increase in gastrointestinal disorders, and rise in geriatric population, which propels the market growth. In addition, increase in product approval is expected to boost the market growth in the near future.
The major factor that fuels the growth of the Endoscopic Retrograde Cholangiopancreatography Market includes Increase in number of patients suffering from chronic disease and technological advancements in endosocpe and endotherpay devices primarily drive the growth of the Endoscopic Retrograde Cholangiopancreatography market. Similarly, surge in focus on personalized medicines for early detection of disease, selection of appropriate treatment, and determination of prognosis of the therapy are further expected to boost the market growth.
Yes, Endoscopic Retrograde Cholangiopancreatography companies are profiled in the report.
Olympus Corporation, Boston Scientific Corporation, Fujifilm Holdings Corporation, Cook Medical, and Conmed Corporation held a high market position in 2019.
Endotherapy Devices and endoscopes segment is the most influencing segment, owing to to increase in investments by the major players in the development of technologically advanced products as well as rising prevelance of diseases related to bile and pancreatic duct which fuels the growth of this segment.
The total market value of Endoscopic Retrograde Cholangiopancreatography Market is $1,213 million in 2019.
The forcast period for Endoscopic Retrograde Cholangiopancreatography Market is 2020 to 2027
The market value of Endoscopic Retrograde Cholangiopancreatography Market in 2020 is $1,139 million.
The base year is 2019 in Endoscopic Retrograde Cholangiopancreatography Market
Loading Table Of Content...
